Motley Fool
OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
📊
AI Sentiment
Positive
6/10
- Home
- EWTX
as of 02-26-2026 3:51pm EST
$29.91
$0.21
-0.71%
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 3.3B | IPO Year: | 2021 |
| Target Price: | $34.71 | AVG Volume (30 days): | 691.3K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | -12.41 |
| 52 Week Low/High: | $10.60 - $31.82 | Next Earning Date: | 05-27-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -26.20 | Index: | N/A |
| Free Cash Flow: | -144072000.0 | FCF Growth: | N/A |
AI-Powered EWTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.21%
74.21%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
Edris Badreddin
Sell
Director
EWTX Jan 21, 2026
Avg Cost/Share
$29.44
Shares
115,471
Total Value
$3,399,466.24
Owned After
121,601
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Edris Badreddin | EWTX | Director | Jan 21, 2026 | Sell | $29.44 | 115,471 | $3,399,466.24 | 121,601 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
Compare EWTX vs Leading Stocks
See how EWTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.